Population Pharmacodynamic Analysis of Uric Acid–Lowering Effects of Febuxostat Based on Electronic Medical Records in Two Hospitals

Shota Muraki, Kuniaki Moriki, Saki Shigematsu, Masato Fukae, Makoto Kakara, Daiki Yamashita, Takeshi Hirota, Hiroshi Takane, Miki Shimada, Masaaki Hirakawa, Ichiro Ieiri

研究成果: ジャーナルへの寄稿記事

抄録

The aim of this study was to develop a population pharmacodynamic (PPD) model to describe uric acid (UA)–lowering effects in patients treated with febuxostat based on electronic medical records in 2 independent hospitals (university and city hospitals). Interhospital differences in the PPD model were also evaluated. We conducted the following 2 approaches to build the PPD models. A PPD model was developed separately using individual hospital data, and structural models and covariates between the two hospitals were compared (approach A). Another PPD model was developed using all available data from both hospitals, and differences between the 2 hospitals were evaluated by performing a covariate analysis on all PPD parameters (approach B). PPD analyses were performed by NONMEM using data from 358 patients. In both approaches, one indirect response model was established. In approach A, 2 diuretics (loops and thiazides) and renal function tests (Scr or BUN) were selected as covariates for the UA baseline level (serum UA levels just before the febuxostat treatment), whereas 2 diuretics and BUN were selected in approach B. A covariate analysis indicated that loops and thiazides increased UA baseline levels by 7%–14% and 6%–11%, respectively. In approach B, “hospital” was identified as a significant covariate for the UA baseline level; the baseline level was 7% higher in the city hospital. A PPD analysis may provide a precise description of the time course of the UA-lowering effects of febuxostat and quantitatively detect an interhospital difference in the UA baseline level.

元の言語英語
ページ(範囲)304-313
ページ数10
ジャーナルJournal of Clinical Pharmacology
58
発行部数3
DOI
出版物ステータス出版済み - 3 1 2018

Fingerprint

Electronic Health Records
Uric Acid
Population
Blood Urea Nitrogen
Urban Hospitals
Sodium Potassium Chloride Symporter Inhibitors
Thiazides
Sodium Chloride Symporter Inhibitors
Febuxostat
Structural Models
Diuretics
Kidney
Serum

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

これを引用

Population Pharmacodynamic Analysis of Uric Acid–Lowering Effects of Febuxostat Based on Electronic Medical Records in Two Hospitals. / Muraki, Shota; Moriki, Kuniaki; Shigematsu, Saki; Fukae, Masato; Kakara, Makoto; Yamashita, Daiki; Hirota, Takeshi; Takane, Hiroshi; Shimada, Miki; Hirakawa, Masaaki; Ieiri, Ichiro.

:: Journal of Clinical Pharmacology, 巻 58, 番号 3, 01.03.2018, p. 304-313.

研究成果: ジャーナルへの寄稿記事

Muraki, S, Moriki, K, Shigematsu, S, Fukae, M, Kakara, M, Yamashita, D, Hirota, T, Takane, H, Shimada, M, Hirakawa, M & Ieiri, I 2018, 'Population Pharmacodynamic Analysis of Uric Acid–Lowering Effects of Febuxostat Based on Electronic Medical Records in Two Hospitals', Journal of Clinical Pharmacology, 巻. 58, 番号 3, pp. 304-313. https://doi.org/10.1002/jcph.1023
Muraki, Shota ; Moriki, Kuniaki ; Shigematsu, Saki ; Fukae, Masato ; Kakara, Makoto ; Yamashita, Daiki ; Hirota, Takeshi ; Takane, Hiroshi ; Shimada, Miki ; Hirakawa, Masaaki ; Ieiri, Ichiro. / Population Pharmacodynamic Analysis of Uric Acid–Lowering Effects of Febuxostat Based on Electronic Medical Records in Two Hospitals. :: Journal of Clinical Pharmacology. 2018 ; 巻 58, 番号 3. pp. 304-313.
@article{2b0a73b03bbe436bb8ab9e99022c41b3,
title = "Population Pharmacodynamic Analysis of Uric Acid–Lowering Effects of Febuxostat Based on Electronic Medical Records in Two Hospitals",
abstract = "The aim of this study was to develop a population pharmacodynamic (PPD) model to describe uric acid (UA)–lowering effects in patients treated with febuxostat based on electronic medical records in 2 independent hospitals (university and city hospitals). Interhospital differences in the PPD model were also evaluated. We conducted the following 2 approaches to build the PPD models. A PPD model was developed separately using individual hospital data, and structural models and covariates between the two hospitals were compared (approach A). Another PPD model was developed using all available data from both hospitals, and differences between the 2 hospitals were evaluated by performing a covariate analysis on all PPD parameters (approach B). PPD analyses were performed by NONMEM using data from 358 patients. In both approaches, one indirect response model was established. In approach A, 2 diuretics (loops and thiazides) and renal function tests (Scr or BUN) were selected as covariates for the UA baseline level (serum UA levels just before the febuxostat treatment), whereas 2 diuretics and BUN were selected in approach B. A covariate analysis indicated that loops and thiazides increased UA baseline levels by 7{\%}–14{\%} and 6{\%}–11{\%}, respectively. In approach B, “hospital” was identified as a significant covariate for the UA baseline level; the baseline level was 7{\%} higher in the city hospital. A PPD analysis may provide a precise description of the time course of the UA-lowering effects of febuxostat and quantitatively detect an interhospital difference in the UA baseline level.",
author = "Shota Muraki and Kuniaki Moriki and Saki Shigematsu and Masato Fukae and Makoto Kakara and Daiki Yamashita and Takeshi Hirota and Hiroshi Takane and Miki Shimada and Masaaki Hirakawa and Ichiro Ieiri",
year = "2018",
month = "3",
day = "1",
doi = "10.1002/jcph.1023",
language = "English",
volume = "58",
pages = "304--313",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "3",

}

TY - JOUR

T1 - Population Pharmacodynamic Analysis of Uric Acid–Lowering Effects of Febuxostat Based on Electronic Medical Records in Two Hospitals

AU - Muraki, Shota

AU - Moriki, Kuniaki

AU - Shigematsu, Saki

AU - Fukae, Masato

AU - Kakara, Makoto

AU - Yamashita, Daiki

AU - Hirota, Takeshi

AU - Takane, Hiroshi

AU - Shimada, Miki

AU - Hirakawa, Masaaki

AU - Ieiri, Ichiro

PY - 2018/3/1

Y1 - 2018/3/1

N2 - The aim of this study was to develop a population pharmacodynamic (PPD) model to describe uric acid (UA)–lowering effects in patients treated with febuxostat based on electronic medical records in 2 independent hospitals (university and city hospitals). Interhospital differences in the PPD model were also evaluated. We conducted the following 2 approaches to build the PPD models. A PPD model was developed separately using individual hospital data, and structural models and covariates between the two hospitals were compared (approach A). Another PPD model was developed using all available data from both hospitals, and differences between the 2 hospitals were evaluated by performing a covariate analysis on all PPD parameters (approach B). PPD analyses were performed by NONMEM using data from 358 patients. In both approaches, one indirect response model was established. In approach A, 2 diuretics (loops and thiazides) and renal function tests (Scr or BUN) were selected as covariates for the UA baseline level (serum UA levels just before the febuxostat treatment), whereas 2 diuretics and BUN were selected in approach B. A covariate analysis indicated that loops and thiazides increased UA baseline levels by 7%–14% and 6%–11%, respectively. In approach B, “hospital” was identified as a significant covariate for the UA baseline level; the baseline level was 7% higher in the city hospital. A PPD analysis may provide a precise description of the time course of the UA-lowering effects of febuxostat and quantitatively detect an interhospital difference in the UA baseline level.

AB - The aim of this study was to develop a population pharmacodynamic (PPD) model to describe uric acid (UA)–lowering effects in patients treated with febuxostat based on electronic medical records in 2 independent hospitals (university and city hospitals). Interhospital differences in the PPD model were also evaluated. We conducted the following 2 approaches to build the PPD models. A PPD model was developed separately using individual hospital data, and structural models and covariates between the two hospitals were compared (approach A). Another PPD model was developed using all available data from both hospitals, and differences between the 2 hospitals were evaluated by performing a covariate analysis on all PPD parameters (approach B). PPD analyses were performed by NONMEM using data from 358 patients. In both approaches, one indirect response model was established. In approach A, 2 diuretics (loops and thiazides) and renal function tests (Scr or BUN) were selected as covariates for the UA baseline level (serum UA levels just before the febuxostat treatment), whereas 2 diuretics and BUN were selected in approach B. A covariate analysis indicated that loops and thiazides increased UA baseline levels by 7%–14% and 6%–11%, respectively. In approach B, “hospital” was identified as a significant covariate for the UA baseline level; the baseline level was 7% higher in the city hospital. A PPD analysis may provide a precise description of the time course of the UA-lowering effects of febuxostat and quantitatively detect an interhospital difference in the UA baseline level.

UR - http://www.scopus.com/inward/record.url?scp=85031498761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031498761&partnerID=8YFLogxK

U2 - 10.1002/jcph.1023

DO - 10.1002/jcph.1023

M3 - Article

VL - 58

SP - 304

EP - 313

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 3

ER -